Boothbay Fund Management LLC Has $556,000 Position in Alector, Inc. (NASDAQ:ALEC)

Boothbay Fund Management LLC grew its position in Alector, Inc. (NASDAQ:ALEC - Free Report) by 562.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 294,156 shares of the company's stock after acquiring an additional 249,756 shares during the quarter. Boothbay Fund Management LLC owned approximately 0.30% of Alector worth $556,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. raised its stake in Alector by 64.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company's stock valued at $12,716,000 after acquiring an additional 1,072,298 shares in the last quarter. Renaissance Technologies LLC grew its position in Alector by 63.0% in the 4th quarter. Renaissance Technologies LLC now owns 915,738 shares of the company's stock valued at $1,731,000 after buying an additional 353,988 shares in the last quarter. Diadema Partners LP acquired a new stake in shares of Alector in the 4th quarter worth approximately $452,000. Dimensional Fund Advisors LP boosted its holdings in shares of Alector by 21.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 882,120 shares of the company's stock valued at $1,667,000 after acquiring an additional 157,231 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Alector by 8.5% during the third quarter. Geode Capital Management LLC now owns 1,903,942 shares of the company's stock valued at $8,874,000 after acquiring an additional 148,357 shares during the period. 85.83% of the stock is currently owned by institutional investors.

Alector Price Performance

NASDAQ:ALEC traded down $0.05 during trading hours on Tuesday, reaching $1.12. The company's stock had a trading volume of 208,213 shares, compared to its average volume of 803,064. Alector, Inc. has a one year low of $0.87 and a one year high of $6.78. The business's 50-day moving average is $1.22 and its 200-day moving average is $2.18. The company has a market cap of $111.49 million, a price-to-earnings ratio of -0.66 and a beta of 0.76.

Alector (NASDAQ:ALEC - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.59. The company had revenue of $54.24 million for the quarter, compared to analyst estimates of $20.41 million. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. On average, sell-side analysts predict that Alector, Inc. will post -1.88 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on ALEC. Morgan Stanley reaffirmed an "underweight" rating and issued a $1.50 price objective (down previously from $3.00) on shares of Alector in a research note on Friday, March 7th. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Alector in a research report on Thursday, February 27th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, Alector presently has a consensus rating of "Hold" and a consensus target price of $3.50.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.